New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
12:14 EDTQCOR, UNH, MNKUnitedHealth updates policy, says Acthar isn't medically necessary in MS
In an updated drug policy with an effective date of August 1, UnitedHealthcare (UNH) stated that it does not view Questcor's (QCOR) H.P. Acthar gel as medically necessary for treatment of acute exacerbations of multiple sclerosis. "Published clinical evidence does not demonstrate superiority of Acthar to other available corticosteroids," UnitedHealthcare stated in its bulletin. Note that Mallinckrodt (MNK) has proposed a merger with Questcor. UnitedHealthcare's website cites June 23 as the published date of the new drug policy for Acthar. Reference Link
News For QCOR;UNH;MNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 16, 2014
06:10 EDTUNHUnitedHealth reports Q3 Employer & Individual revenue $10.6B
Subscribe for More Information
06:08 EDTUNHUnitedHealth: Affordable Care Act reduced Q3 by 80 basis points
Subscribe for More Information
06:07 EDTUNHUnitedHealth sees FY14 EPS $5.60-$5.65, consensus $5.58
Subscribe for More Information
06:01 EDTUNHUnitedHealth reports Q3 EPS $1.63, consensus $1.53
Subscribe for More Information
October 15, 2014
15:28 EDTUNHNotable companies reporting before tomorrow's open
Subscribe for More Information
06:42 EDTMNKMallinckrodt valuation remains compelling, says Piper Jaffray
Piper Jaffray believes Mallinckrodt's outlook for FY15 is conservative and that the risk/reward on shares is compelling. The firm raised its price target for the stock to $109 from $105 following the company's investor day and reiterates an Overweight rating on the name.
October 14, 2014
11:13 EDTMNKMallinckrodt management to meet with UBS
Subscribe for More Information
09:40 EDTMNKMallinckrodt aims to drive 'modest' growth in specialty controlled generics
Says aiming for profitability and revenue growth. Will continue to expand its pain management business. Looking to increase shareholder value, patient solutions and to drive top-line growth. Says aims to develop and acquire "durable, late stage complex products." Looking to invest in pipeline extensions of key portfolio assets. Aims to divest lower margin, slower growing business. Says sees future expansion in ophthalmology and dermatology. Looks to actively divest lower-growth businesses. Says durable assets, platforms positioned for sustained Specialty Pharmaceuticals growth. Says OFIRMEV is well positioned for growth in FY15 and beyond. Aims to up Acthar growth and initiate commercial efforts. Plans to enhance its science and technology investment. Comments made during the company's investor briefing.
07:34 EDTMNKMallinckrodt to host conference call
Subscribe for More Information
07:05 EDTUNHUnitedHealth October volatility elevated into Q3 and guidance
Subscribe for More Information
07:02 EDTMNKMallinckrodt sees FY15 adjusted EPS $6.70-$7.20, consensus $6.80
Subscribe for More Information
06:03 EDTMNKMarket overreacted to new Irish tax rules, says BMO Capital
BMO Capital believes the market may have overreacted yesterday to the report that Ireland is eliminating the "Double Irish" tax loophole. The firm says Allergan (AGN) confirmed that it incorporated potential changes to Irish tax law in its recently raised earnings guidance while Mallinckrodt (MNK) said it does expect the new tax structure to have an immediate impact. BMO views yesterday's pullback in shares of Allergan, Mallinckrodt and Actavis (ACT) as an overreaction.
October 13, 2014
07:15 EDTUNHNational Association of Corporate Directors to hold a conference
Subscribe for More Information
October 10, 2014
07:16 EDTMNKAmerican Society of Plastic Surgeons to hold annual meeting
Annual Meeting of ASPS is being held in Chicago on October 10-14.
October 9, 2014
06:39 EDTMNKMallinckrodt price target raised to $110 from $95 at Jefferies
Jefferies raised its price target for Mallinckrodt shares to $110 ahead of the company's October 14 analyst day and keeps a Buy rating on the name. The firm says recent trends show continued strength for Ofirmev.
06:33 EDTUNHMaximus appoints Kelly Clark as new Chief Information Officer
Subscribe for More Information
October 8, 2014
07:19 EDTMNKCBI to hold a conference
Subscribe for More Information
October 7, 2014
10:02 EDTUNHOn The Fly: Analyst Initiation Summary
Subscribe for More Information
October 6, 2014
16:05 EDTUNHUnitedHealth initiated with an Overweight at Piper Jaffray
Subscribe for More Information
11:21 EDTMNKMallinckrodt to host investor meeting
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use